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Abstract
BACKGROUND
Management of chronic total occlusions (CTO) in diabetics is challenging, with a
recent trend towards early revascularization [ER: Percutaneous coronary
intervention (PCI) and bypass grafting] instead of optimal medical therapy
(OMT). We hypothesize that ER improves morbidity and mortality outcomes in
diabetic patients with CTOs as compared to OMT.
AIM
To determine the long term clinical outcomes and to compare morbidity and
mortality between OMT and ER in diabetic patients with CTOs.
METHODS
Potentially relevant published clinical trials were identified in Medline, Embase,
chemical abstracts and Biosis (from start of the databases till date) and pooled
hazard ratios (HR) computed using a random effects model, with significant P
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value < 0.05. Primary outcome of interest was all-cause death. Secondary
outcomes included cardiac death, prompt revascularization (ER) or repeat
myocardial infarction (MI). Due to scarcity of data, both Randomized control
trials and observational studies were included. 4 eligible articles, containing 2248
patients were identified (1252 in OMT and 1196 in ER). Mean follow-up was 45-60
mo.
RESULTS
OMT was associated with a higher all-cause mortality [HR: 1.70, 95% confidence
interval (CI): 0.80-3.26, P = 0.11] and cardiac mortality (HR: 1.68, 95%CI: 0.96-2.96,
P = 0.07). Results were close to significance. The risk of repeat MI was almost the
same in both groups (HR: 0.97, 95%CI: 0.61-1.54, P = 0.90). Similarly, patients
assigned to OMT had a higher risk of repeat revascularization (HR: 1.62, 95%CI:
1.36-1.94, P < 0.00001). Sub-group analysis of OMT vs PCI demonstrated higher
all-cause (HR: 1.98, 95%CI: 1.36-2.87, P = 0.0003) and cardiac mortality (HR: 1.87,
95%CI: 0.96-3.62, P = 0.06) in the OMT group. The risk of repeat MI was low in the
OMT group vs PCI (HR: 0.53, 95%CI: 0.31-0.91, P = 0.02). Data on repeat
revascularization revealed no difference between the two (HR: 1.00, 95%CI: 0.521.93, P = 1.00).
CONCLUSION
In diabetic patients with CTO, there was a trend for improved outcomes with ER
regarding all-cause and cardiac death as compared to OMT. These findings were
reinforced with statistical significance on subgroup analysis of OMT vs PCI.
Key Words: Coronary angiography; Diabetes mellitus; Percutaneous coronary Intervention;
Coronary bypass grafts; Chronic total occlusions; Mortality
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
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Core Tip: There is a well-known association with worse outcomes from chronic total
occlusions in diabetics. These lesions have been traditionally treated with optimal
medical therapy (OMT) with the standard of care for revascularization being coronary
artery bypass grafting with little evidence of superiority over OMT. Our results reveal
for the first time a trend towards superiority of the prompt revascularization group to
OMT in terms of all cause and cardiac death in diabetics with chronic total occlusions.
These findings were reinforced on subgroup analysis. However, patients undergoing
percutaneous coronary intervention had a higher risk of repeat fatal and non-fatal
myocardial infarction as compared to OMT. The risk for repeat revascularization was
similar in both groups.

Citation: Khan MS, Sami FA, Singh H, Ullah W, Al-Dabbas M, Changal KH, Mir T, Ali Z,
Kabour A. Medical therapy vs early revascularization in diabetics with chronic total occlusions:
A meta-analysis and systematic review. World J Cardiol 2020; 12(11): 559-570
URL: https://www.wjgnet.com/1949-8462/full/v12/i11/559.htm
DOI: https://dx.doi.org/10.4330/wjc.v12.i11.559

INTRODUCTION
Chronic total occlusion (CTO) of a coronary artery is defined as a 100% stenosis with
thrombolysis in myocardial infarction 0/I flow for greater than 3 mo[1,2]. The
prevalence of CTOs ranges from 18%-26% in all patients with coronary artery disease
(CAD) and almost 50% in patients with previous coronary artery bypass grafting
(CABG)[3]. Around 10% of patients with acute myocardial infarction (MI) are also
found to have CTOs[3]. Presence of CTO is associated with lifestyle impairment,
reduced cardiac performance and poor long-term outcomes[3,4]. Given the complex
nature and uncertainty regarding mortality benefit from revascularization, these
lesions were traditionally treated with optimal medical therapy (OMT). However, with
recent advancement in percutaneous techniques and greater operator experience along
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with better patient selection, there has been an increase in the trend of CTO
interventions in contemporary practice.
In this complex subset of CAD population, diabetic patients are particularly at
higher risk of poor outcomes as compared to their non-diabetic counter-parts[5-7].
Despite lack of sufficient studies, recent evidence suggest that successful CTO
revascularization is associated with improved outcomes of quality of life, left
ventricular systolic function and potentially survival in general population[8,9].
However, limited data exists regarding long-term outcomes in diabetic patients with
CTO treated with revascularization. We, therefore, conducted this meta-analysis of
randomized clinical and observational studies to compare clinical outcomes with
revascularization vs optimal medical therapy in diabetic patients with CTO.

MATERIALS AND METHODS
We followed the preferred reporting items for systematic reviews and meta-analyses
guidelines, a checklist of which is available as supplementary material[10].

Search strategy
A predefined inclusion criterion was established in advance. Potentially relevant
published clinical trials were identified in Medline, Embase, chemical abstracts and
Biosis (from start of the databases till date). The following search items were used to
search titles and abstracts: (Optimal medical therapy? or OMT? Or intensive medical
therapy or IMT or revascularization? Or prompt revascularization or early
revascularization? And diabetic or type 2 diabetes or DM and chronic total occlusion
or CTO and clinical trials. Due to scarcity of data, both observational and
interventional studies were included. Studies were limited to involving humans only.

Selection criteria
Two researchers independently performed an electronic search of pub med and web of
science databases. No language restrictions were made. Studies were included if they
met the following criteria; intervention with OMT and early revascularization (PCI or
CABG) in diabetics as variables and primary outcome of interest as all cause death.
Secondary outcomes included cardiac death, prompt revascularization (ER) or repeat
MI. Studies were included if successful revascularization (CABG or PCI) was
performed within six weeks of randomization or start of study. Both short and long
term follow ups were included in literature review. 48 articles were identified after the
search. The second selection step involved proof-reading of those articles to ensure the
first step was performed correctly. Articles were excluded if data on OMT or prompt
revascularization (ER) was missing, trials did not include diabetic subjects or primary
and secondary outcomes of interest were not available. In case of un-clarity, inclusion
of the studies was discussed amongst the authors to arrive at a final decision.

Data extraction and statistical analysis
Data was extracted from each study using a standardized spread sheet which involved
study identification (Author, year of publication and country), study type, percent
males, subject baseline characteristics with history of coronary artery disease, number
of cases in OMT and ER arms, time of follow up, type of stent used (Drug eluting vs
bare-metal), exclusion criteria and quality scoring.
To calculate the overall effect outcome, generic inverse variance tool under the
random effects model to calculate pooled hazard ratios (HR) was performed using
Cochrane's review manager. The “test for overall effect” was reported as z value
corroborating inference from the 95% confidence interval (CI), and the probability
value of P < 0.05 was considered statistically significant. Higgins I-squared (I2) statistic
model was used to assess variations in outcomes of included studies. I2 values of 50%
or less corresponded to low to moderate, and 75% or higher indicated large amounts
of heterogeneity. Publication bias was illustrated graphically using a funnel plot
asymmetry. The methodological quality of included articles was performed using the
Cochrane guidelines for systematic review and meta-analysis.
We also assessed quality using a scoring system based on the Delphi consensus for
meta-analysis[11]. The following criteria were used for scoring: Proper randomization
(Score: 1 point), similarity of treatment groups in relevant variables at baseline (1
point), blinding of subjects and investigators (1 point for each), specified eligibility
criteria (1 point), valid point estimates and measures of variability (1 point) and data
on degree of compliance (1 point). Thus, a combined score was calculated for each
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study which could range from 0 to 7 points. For the observational studies, a score of 0
was given for randomization. Quality scores for each study have been illustrated in
Table 1.

RESULTS
The search through Pub med and Med of science databases yielded 48 potentially
relevant articles. Based on predefined exclusion criteria, 44 papers were excluded for
various reasons. 1 Randomized control trial[12] and 3 observational studies[13-15]
involving a total of 2448 subjects were included in the meta-analysis. The number of
subjects ranged from 236 in Yan et al[15] to 972 in Damluji et al[12]. Mean age ranged from
59.2 years in Yan et al[15] to 68.5 years in Flores-Umanzor et al[13] Reported compliance
was 100%. Follow up time ranged from 45 mo in Yan et al[15] To 60 mo in Damluji et al[12]
as above, studies were included if successful revascularization (CABG or PCI) was
performed within six weeks of randomization or start of study. OMT included
pharmacological therapy as well as lifestyle modification. Pharmacologic therapy
across the studies included antiplatelet therapy (as needed), maximum tolerated dose
of anti-anginals (B-Blocker plus a long acting nitrate and/or a calcium channel
blocker) and statins. Baseline characteristics of all studies have been illustrated in
Table 1, with the major co-morbidities across all studies in Table 2. Among studies
with reported data, right coronary artery was the vessel most commonly diseased
(Table 3).

Primary effect outcome
Three out of four studies reported long term all-cause mortality. There was a 70%
increase in risk of pooled all-cause mortality in the OMT group, although the
confidence interval did cross 1, (HR: 1.70, 95%CI: 0.80-3.26, P = 0.11, see Figure 1A).
Significant heterogeneity was observed, (I2= 88%, P = 0.0003). After removing the
study by Flores-Umanzor et al[13], no significant heterogeneity was seen, (I2= 28%, P =
0.24) however, pooled results were similar, (HR: 1.21, 95%CI: 0.79-4.19, P = 0.38,
Figure 1B). In order to assess for publication bias, a funnel plot for each study was
constructed against their respective precisions. Absence of publication bias is reflected
in an intercept close to zero with the slope of regression line close to overall effect size.
Although the small number of studies limited its interpretation however, a subjective
impression of funnel plot demonstrated no publication bias.

Secondary effect outcomes
All four studies reported long term cardiac mortality. The long-term HR for cardiac
mortality was 1.68 with 95%CI: 0.96-2.96 and P = 0.07 in the OMT group with an
overall 68% increased risk as compared to the ER group, results were close to
significance (Figure 1C). Significant heterogeneity was again observed, (I2= 76%, P =
0.006). After removing Flores-Umanzor et al[13] from the analysis, mortality was higher
in the OMT group, however the CI crossed 1, (HR: 1.24, 95%CI: 0.85-1.81, P = 0.27).
Data for repeat MI was available for all four studies. No significant differences in
the hazard ratio were observed between the two groups. (HR: 0.97, 95%CI: 0.61-1.54, P
= 0.90, Figure 2A). No significant heterogeneity was observed, (I2= 41%, P = 0.16).
All four studies reported data on repeat revascularization (PCI and CABG). There
was a 62% increase in risk of repeat revascularization in patients assigned to medical
therapy, and results were statistically significant, (HR: 1.62, 95%CI: 1.36-1.94, P <
0.00001, Figure 2B). No publication bias or study heterogeneity was observed, I2= 0%.

Subgroup analysis
Sub-group analysis stratified by mode of revascularization i.e. CABG or PCI was also
performed for both primary and secondary effect outcomes. Only Flores-Umanzor
et al[13] provided data on both PCI and CABG where as two studies provided data on
PCI only. Thus, subgroup analysis was done only for PCI.
For all-cause mortality, sub group analysis of OMT vs PCI revealed a 98% increased
risk in the OMT group, (HR: 1.98, 95%CI: 1.36-2.87, P = 0.0003, Figure 3A). This was
statistically significant with no significant heterogeneity, (I2= 0, P = 0.83).
Similarly, sub-group analysis for cardiac mortality was also done comparing PCI vs
OMT. Three out of four studies i.e., Flores-Umanzor et al[13] and Yan et al[15] provided
data on PCI. There was an 87% increased risk of cardiac mortality in the OMT vs PCI
group, (HR: 1.87, 95%CI: 0.96-3.62, P = 0.06, Figure 3B). Results were not statistically
significant with moderate heterogeneity, (I2= 60%, P = 0.08).
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Table 1 Baseline characteristics of all studies
FloresUmanzor

Damluji et al[12]

Ref.

Yan et al[15]

Choi et al[14]

et al[13]
Type of
study

Randomized control trial (Post Hoc
analysis of BARI-2D)

Cohort
(prospective)

Cohort (retrospective)

Cohort (retrospective)

Country

United States

Spain

China

South Korea

Period
during
which study
was done

2001-05

2010-14

2007-17

2003-12

Study size
(Patients
with DM
and CTO)

972

538

2361

702

Follow up in
months

60

48

45

46

Male (%)

78

82

78

77

Age, mean
(yr)

62.5

68.5+/-3.5

60

64.6

Type of stent DES or BMS
used if PCI

-

DES

DES

Exclusion
criteria

Need for immediate revascularization,
left main coronary disease, a creatinine
level > 2.0 mg/dL, a glycated
hemoglobin level > 13.0%, heart failure
class III or IV, hepatic dysfunction, or
previous PCI or CABG within the last 12
mo

No exclusion
criteria

(1) Patients who had a history of CABG; (2)
Patients who had acute myocardial infarction
(MI) due to non-CTO vessels 1 mo before the
study; (3) Patients who had left main
coronary artery disease; and (4) Patients who
had histories of cancer or other diseases that
could confuse the end points

History of previous CABG;
history of cardiogenic shock or
cardiopulmonary resuscitation;
ST-segment elevation acute MI
during the preceding 48 h

Quality
score2

7

5

5

5

1

Propensity Matched Population.
Criteria used for scoring: Proper Randomization (Score: 1 point), similarity of treatment groups in relevant variables at baseline (1 point), blinding of
subjects and investigators (1 point for each), specified eligibility criteria (1 point), valid point estimates and measures of variability (1 point) and data on
degree of compliance (1 point). More details in text. DM: Diabetes mellitus; CTO: Chronic total occlusion; PCI: Percutaneous coronary intervention; RCT:
Randomized control trial; DES: Drug eluting stent; BMS: Bare metal stent; CABG: Coronary artery bypass grafting.
2

Three out of four studies i.e. Flores-Umanzor et al[13], Choi et al[14] and Yan et al[15]
provided data on risk of repeat MI. OMT was relatively safer in regards to occurrence
of repeat MI as compared with PCI with a decreased HR, (HR: 0.53, 95%CI: 0.31-0.91, P
= 0.02, Figure 3C). No heterogeneity was observed, I2= 0%, P = 0.87.
For repeat revascularization, sub group analysis of OMT vs PCI revealed no
difference in HR between the two groups. (HR: 1.00, 95%CI: 0.52-1.93, P = 1.00,
Figure 3D).

DISCUSSION
In this meta-analysis of randomized controlled and observational studies comparing
diabetic patients with CTOs, patients in the OMT group were found to have a higher
risk of all-cause and cardiac death as compared to ER. We included 4 studies for a total
of 2448 patients. 1252 patients were treated with OMT while 1196 patients underwent
early revascularization. Damluji et al[12] which is a post hoc analysis of the bypass
angioplasty revascularization investigation 2 diabetes trial, evaluated the influence of
CTO on long term clinical outcomes of patients with coronary artery disease and
diabetes mellitus. We extracted the data for CTO only from Damluji et al[12] to calculate
mortality and morbidity outcomes in diabetics, however, our results were nonsignificant as shown in Figures 1A-1C further 3 observational studies were added to
our meta-analysis to achieve the above results. We found that there was a trend of
improved survival with ER either with CABG or PCI in terms of cardiac and all cause
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Table 2 Percentage prevalence of co-morbidities across studies (actual prevalence in brackets)
1

Flores-

Damluji
Ref.

[12]

et al

Umanzor et al

OMT (n = 490) ER (n =
482)

OMT (n = 326)

Yan

Choi
[15]

et al[14]

et al

[13]

ER

ER

OMT (n =
118)

ER (n =
118)

OMT (n =
318)

ER (n =
384)

PCI (n = 76)

CABG (n =
136)

82 ( 62)

86 (117)

66.9 (79)

71.2 (84)

70.7 (225)

70.3 (270)

28 (21)

56.8 (67)

55.9 (66)

34.9 (111)

18.0 (69)

HTN

80 (385)

81 (387)

85 (276)

Previous MI

44 (214)

41 (197)

33 (108)

Prior CHF

7 (36)

9 (43)

-

-

-

14.4 (17)

10.2 (12)

-

-

Prior Stent/PCI

11 (56)

12 (59)

-

-

-

48.3 (57)

42.4 (50)

30.5 (97)

22.1 (85)

Prior CVA/TIA

10 (49)

10 (46)

-

-

-

5.1 (6)

5.9 (7)

12.3 (39)

11.2 (43)

Prior Revascularizatio

31 (151)

26 (124)

-

-

-

-

-

-

-

Prevnious CABG

-

-

14 (45)

5 (4)

4 (5)

-

-

0

0

HbA1c mean

7.4

7.3

7.6 ± 0.1

7.6 ± 0.2

7.3 ± 0.1

-

-

-

-

Dyslipidemia

83 (402)

84 (400)

75 (246)

71 (54)

74 (100)

51.7 (61)

50 (59)

21.7 (69)

31.3 (120)

Smoking

-

-

52 (169)

55 (42)

59 (80)

55.9 (66)

57.6 (68)

28.6 (91)

32.8 (126)

Peripheral vascular
disease

-

-

45 (145)

33 (25)

35 (47)

3.4 (4)

3.4 (4)

6.0 (19)

3.4 (13)

28 (21)

1

Data given separately for percutaneous coronary intervention and Coronary Artery Bypass Grafting group. OMT: Optimal medical therapy; ER: Early
revascularization; N: Number of subjects; PCI: Percutaneous coronary intervention; CABG: Coronary Artery Bypass Grafting; HTN: Hypertension; MI:
Myocardial infarction; CHF: Heart failure; CVA: Cerebrovascular accident, HbA1c: Hemoglobin A1c.

Table 3 Chronic total occlusions location with number of chronic total occlusions lesions among studies in percentages (actual
prevalence in brackets)
Flores-Umanzor
Damluji et al[12]

Ref.

Yan et al[15]

et al[13]

OMT

ER

OMT (n = 326)

ER (n = 212) OMT (n =
118)

1

-

-

80 (261)

2

-

-

3

-

LAD artery

Choi et al[14]
ER (n =
118)

OMT (n =
318)

ER (n = 384)

75 (159)

-

-

79 (60)

24 (50)

-

-

-

1.5 (5)

1.4 (3)

-

-

-

-

18 (60)

24 (51)

30.5 (36)

28.0 (33)

26.4 (84)

38.5 (148)

LCX artery

-

-

19 (62)

20 (42)

28.0 (33)

26.3 (31)

36.5 (116)

29.2 (112)

RCA

-

-

52 (170)

47 (100)

41.5 (49)

45.8 (54)

56.3 (117)

47.9 (184)

Other coronary artery
branches

-

-

10 (34)

9 (19)

-

-

-

-

Number of CTO lesions

CTO location

LAD: Left anterior descending; LCX: Left circumflex; RCA: Right coronary artery; OMT: Optimal medical therapy; ER: Early revascularization; N: number
of subjects.
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death. To our knowledge, this is the first ever meta-analysis of clinical trials comparing
morbidity and mortality outcomes in diabetic patients with a CTO. Our subgroup
analysis also revealed poor performance of PCIs vs OMT in terms of incidence of
combined fatal and non-fatal MI. Further stratification could not be performed due to
paucity of data.
Given the complex nature and uncertainty regarding mortality or morbidity benefits
from percutaneous or surgical revascularization, CTO lesions have been traditionally
treated with OMT. Historically, the standard of care for revascularization of CTO
lesions has been CABG with little evidence of superiority over OMT. However, with
recent advancement in percutaneous techniques and greater operator experience along
with better patient selection, there has been an increase in trend of CTO interventions
in contemporary practice[16,17]. Although observational data has shown a reduction in
Major Adverse Cardiac Events, global left ventricular ejection fraction and quality of
life after revascularization of CTO, results from these trials are inconsistent[18,19].
Currently the global expert consensus statement recommends PCI revascularization
for ischemic symptom improvement for which data is more unanimous[20].
Diabetes mellitus is a major risk factor of CTO. Around 34%-40% of patients with
CTO have a history of diabetes[13] and there is a well-known association with worse
outcomes from CTO in diabetics[5-7,13]. Diabetes leads to endothelial cell dysfunction
and changes in microcirculation, a prothrombotic/proinflammatory state along with
impaired formation of coronary collaterals[7,8,21]. This causes aggressive progression of
atherosclerosis within the arterial bed including the coronary arteries leading to poorer
outcomes in patients with CAD[22]. PCI in diabetic patients also has a higher risk of instent restenosis, repeat revascularization, MI, stent thrombosis and death when
compared to non-diabetics[23-25].
By performing a post hoc analysis of the bypass angioplasty revascularization
investigation 2 diabetes trial, Damluji et al[12] was the first to compare clinical outcomes
in patients with both diabetes and coronary artery disease. They found that a lot of
diabetic patients with CAD had a high prevalence of CTOs, approximately 41%.
Although the primary outcome studied was the effect of CTOs on mortality in
diabetics with a strongly positive correlation, we extracted the data for the CTO
subgroup only for our analysis and found that OMT was associated with a higher risk
of all cause and cardiac mortality in diabetics. Patients undergoing early
revascularization were also noted to have a lower risk of repeat MI and repeat
revascularization at long term follow up. Damluji et al[12] and Choi et al[14] however did
not perform a subgroup analysis on the revascularization modality chosen i.e., CABG
vs PCI.
Our subgroup analysis (OMT vs PCI) revealed inferiority of PCI as a
revascularization strategy in terms of repeat MI and repeat revascularization to the
combined PCI and CABG group. This discrepancy in results is an interesting
observation from the PCI subset as compared to the combined revascularization
pool. This could imply superiority of CABG over PCI in these patients but these results
might be confounded by disease anatomy and various comorbidities. Studies designed
to compare CABG and PCI for this purpose can be helpful in the future. Also, the
current success rates of CTO-PCI in the general population are from 80%-85%,
however the majority of our trials demonstrated a lower success rate[26]. One possible
explanation for this discrepancy could be recent advancements in percutaneous
techniques and equipment, however it is well known that diabetic patients have a
higher burden of CAD with more complex disease anatomy which might be difficult
to completely re-vascularize[27]. In a meta-analysis of 35 studies including 89883
patients, Garcia et al[28] demonstrated that CABG was twice as likely as PCI to achieve
complete revascularization in patients with CTOs. The study by Flores-Umanzor
et al[13] included in our meta-analysis also noted higher rates of anatomic and
functional complete revascularization in CABG vs PCI patients (63% and 62% vs 36%
and 32%, P < 0.01). Subsequently, they also reported statistically significant lower allcause and cardiac mortality with CABG when compared to MT group but not with
PCI.
Another important factor to consider in these patients is the presence or absence of
chronic kidney disease (CKD). Studies have shown that renal dysfunction is an
independent risk factor for cardiovascular disease, with higher mortality rates for both
myocardial infarction and sudden cardiac death[29,30]. Our patients in Choi et al[14] and
Yan et al[15] were case-control matched according to the presence or absence of CKD,
however, further data on this sub-group was not available for us to perform analysis.
Similarly, the study referenced by Damluji et al[12] excluded patients with a creatinine
of 2.0 mg/dL or higher. Flores-Umanzor et al[13] did not comment on CKD. Hopefully,
further studies in the future shall enable us to look at the effect of CKD on clinical

WJC

https://www.wjgnet.com

565

November 26, 2020

Volume 12

Issue 11

Khan MS et al. OMT vs ER in diabetics with CTO

Figure 1 Random effects meta-analysis and forest plot of hazard ratios for all cause long term and cardiac mortality. A: All-cause Mortality; B:
All-cause mortality after removing Flores-Umanzor et al[13]; and C: Cardiac Mortality.

Figure 2 Random effects meta-analysis and forest plot of hazard ratios for repeat myocardial infarction and repeat revascularization. A:
Repeat Myocardial Infarction; and B: Repeat revascularization.

outcomes in diabetics with CTO.
It is also not clear why revascularization in CTO is beneficial and associated with
improved survival rates in diabetics. CTOs are usually associated with a larger scar
and most of all with a bigger border zone which causes arrhythmias and sudden
cardiac death in most patients[31]. Thus, it might be the beneficial effects of early
revascularization in preventing the formation of scar myocardium which may lead to
improvement in mortality and morbidity. It also might be worthwhile to attempt
CABG instead of PCI in patients with a difficult anatomy particularly in the diabetic
sub group as these patients have a lower success rate as compared to the general
population and might save unnecessary side effects from an unsuccessful procedure in
itself.

Limitations
Our studies have various limitations. Because of the observational design of three out
of four studies (Figures 1 and 2), there was an inherent risk of selection bias which
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Figure 3 Sub-group analysis and forest plot of hazard ratios for all-cause and cardiac mortality, repeat mi and repeat revascularization. A:
All-Cause Mortality; B: Cardiac mortality; C: Repeat myocardial infarction; and D: Repeat revascularization.

may have affected the results through confounding factors. One of the potential
explanations for the mortality benefits with ER may be potential confounders as highrisk patients are less likely to undergo ER. This was reinstated across all studies as
patients assigned to OMT were older and with more co-morbidities. A major concern
for selection bias in Flores-Umanzor et al[13] was the inclusion of failed PCI group into
the medical therapy group as a failed PCI might itself be a risk factor for adverse
events in the future. Yan and colleagues also only studied one vessel CTO but the
other three studies also included more than one vessel CTO. Although this might not
be significant as Flores-Umanzor et al[13] demonstrated that in majority of patients, only
one vessel was diseased with the most common culprit being the right coronary artery.
The selection of only PCI as revascularization modality by Choi et al[14] and Yan et al[15]
also introduced bias as patients treated with CABG were not studied. Significant
heterogeneity was observed in some effect outcomes, however we used sensitivity
analysis to analyze which study was causing the effect and recalculated data after
dropping the study. Also, as with all met-analysis, the quality of the study is as good
as the quality of the trials itself.

CONCLUSION
Despite our limitations, we report the results of the first meta-analysis specifically
done on diabetic patients with CTO lesions treated with OMT vs ER. The results reveal
a trend towards superiority of the ER group (PCI and CABG) to OMT in terms of all
cause and cardiac death although we could not achieve statistical significance. These
findings were reinforced on subgroup analysis of OMT vs PCI, specifically regards to
all-cause death where the results were statistically significant. However, patients
undergoing PCI had a higher risk of repeat fatal and non-fatal MI as compared to
OMT and the risk for repeat revascularization was similar in both groups.
Overall patients in the OMT only group had a higher risk of repeat revascularization
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as compared to ER group (PCI and CABG). In patients with extensive CAD and CTO,
CABG may be attempted as PCI in diabetics has a higher risk of failure as compared to
non-diabetics. Further data including larger patient population from future studies is
needed to clarify outcome benefits from revascularization or medical therapy in these
patients.

ARTICLE HIGHLIGHTS
Research background
The thought process behind this manuscript was our motivation upon literature
review of a scarcity of data involving clinical outcomes of diabetics with chronic total
occlusion (CTO) of coronary vessels.

Research motivation
Our motivation came from the scarcity of data in this sub group of population. There
exists a lot of literature comparing the mortality and morbidity outcomes of medical
therapy (OMT) vs early re-vascularization [ER: Percutaneous coronary intervention
(PCI) + Coronary artery bypass grafting] in patients with chronic total occlusions but
none in the diabetic subset.

Research objectives
To compare the mortality and morbidity outcomes in diabetic population with CTO
treated with OMT vs ER.

Research methods
Multiple electronic data-bases including Pubmed, Embase were searched involving
human studies comparing OMT vs ER in patients having CTO of coronary vessels.
Data was analyzed using Cochrane review manager with hazard ratios using the
random effects model. Primary effect estimate was all cause mortality with secondary
effect estimates as cardiac mortality, repeat myocardial infarction (MI) and repeat revascularization.

Research results
Statistical analysis revealed a higher risk for all-cause mortality, cardiac mortality and
repeat re-vascularization in the OMT group. For repeat MI, data analysis revealed no
significant differences in between the two groups. Sub-group analysis was also done
for OMT vs PCI. This revealed a higher risk for all-cause mortality but not for
cardiac mortality or repeat re-vascularization in the OMT group. Interestingly, patients
in the OMT group were found to have a lower incidence of repeat MI vs PCI group.

Research conclusions
There is a trend towards superiority of the ER group as compared to OMT group in
diabetic patients with a CTO. These findings were reinforced on sub-group analysis of
OMT vs PCI.

Research perspectives
Despite our limitations, we present the first ever meta-analysis specifically involving
diabetic patients only with CTO treated with OMT or ER. Although we were able to
demonstrate a trend towards superiority of the ER group, this was not statistically
significant for some sub-groups including all-cause and cardiac mortality. Although
this manuscript provides a relatively new insight into management of such patients,
further studies may be needed before a consensus is developed.
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